These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 329649)

  • 1. Are there MAO inhibitors specific for dopamine metabolism?
    Youdim MB; Holzbauer M
    Adv Biochem Psychopharmacol; 1977; 16():349-58. PubMed ID: 329649
    [No Abstract]   [Full Text] [Related]  

  • 2. On the dual nature of monoamine oxidase.
    Knoll J
    Horiz Biochem Biophys; 1978; 5():37-64. PubMed ID: 355087
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of selective monoamine oxidase inhibitors on rat brain mitochondrial monoamine oxidase during hyperbaric oxygenation.
    Goroshinskaya IA; Bronovizkaya ZG; Gorkin VZ
    Commun Psychopharmacol; 1977; 1(1):39-47. PubMed ID: 606471
    [No Abstract]   [Full Text] [Related]  

  • 6. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
    Itzhak Y; Mash D; Zhang SH; Stein I
    Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
    Li XM; Juorio AV; Paterson IA; Boulton AA
    J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
    [No Abstract]   [Full Text] [Related]  

  • 9. Critical role of MAO inhibition in Parkinson's disease.
    Knoll J
    Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
    [No Abstract]   [Full Text] [Related]  

  • 10. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 11. Potentiation of the inhibition of rat liver monoamine oxidase-a by clorgyline after pretreatment with SKF 525A.
    Fowler CJ
    Med Biol; 1980 Oct; 58(5):285-7. PubMed ID: 7206835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
    O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W; Riederer P; Youdim MB
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.
    Murphy DL; Garrick NA; Aulakh CS; Cohen RM
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):37-43. PubMed ID: 6735994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.
    Riederer P; Youdim MB; Birkmayer W; Jellinger K
    Adv Biochem Psychopharmacol; 1978; 19():377-82. PubMed ID: 696465
    [No Abstract]   [Full Text] [Related]  

  • 18. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.